112 related articles for article (PubMed ID: 2683758)
1. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation.
Carpenter CB; Kirkman RL; Shapiro ME; Milford EL; Tiney NL; Waldmann TA; Zimmerman CE; Ramos EL; Strom TB
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):54-7. PubMed ID: 2683758
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
[TBL] [Abstract][Full Text] [Related]
3. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
[No Abstract] [Full Text] [Related]
5. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
7. Effect of anti-IL-2-receptor monoclonal antibody BT 563 in treatment of acute interstitial renal rejection.
Carl S; Wiesel M; Daniel V; Staehler G
Transplant Proc; 1995 Feb; 27(1):854-5. PubMed ID: 7879205
[No Abstract] [Full Text] [Related]
8. Comparison of the immunosuppressive effect of fractionated total lymphoid irradiation (TLI) vs conventional immunosuppression (CI) in renal cadaveric allotransplantation.
Waer M; Vanrenterghem Y; Ang KK; Van der Schueren E; Michielsen P; Vandeputte M
J Immunol; 1984 Feb; 132(2):1041-8. PubMed ID: 6228588
[TBL] [Abstract][Full Text] [Related]
9. In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic.
Ramos EL; Leggat JE; Milford EL; Kirkman RL; Tilney NL; Strom TB; Shapiro ME; Waldmann TA; Carpenter CB
Trans Assoc Am Physicians; 1989; 102():231-9. PubMed ID: 2534707
[No Abstract] [Full Text] [Related]
10. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
11. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
[TBL] [Abstract][Full Text] [Related]
12. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
Waldmann TA; Goldman CK
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation.
Baan CC; Balk AH; van Riemsdijk IC; Vantrimpont PJ; Maat AP; Niesters HG; Zondervan PE; van Gelder T; Weimar W
Transplantation; 2003 May; 75(10):1704-10. PubMed ID: 12777860
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
15. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
Kirkman RL; Shapiro ME; Carpenter CB; McKay DB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
Transplant Proc; 1991 Feb; 23(1 Pt 2):1066-7. PubMed ID: 1989150
[No Abstract] [Full Text] [Related]
16. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
[No Abstract] [Full Text] [Related]
17. The role of a primate model of renal transplantation in the development of new monoclonal antibodies.
Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.
Abouna GM; al-Abdullah IH; Kelly-Sullivan D; Kumar MS; Loose J; Phillips K; Yost S; Seirka D
Transplantation; 1995 Jun; 59(11):1564-8. PubMed ID: 7778170
[TBL] [Abstract][Full Text] [Related]
19. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor.
Knight RJ; Kurrle R; McClain J; Racenberg J; Baghdahsarian V; Kerman R; Lewis R; van Buren CT; Kahan BD
Transplantation; 1994 Jun; 57(11):1581-8. PubMed ID: 8009591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
